Drug intelligence / Profile preview

NM 4651

Development stage: Preclinical
Lead developer: NovelMed Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

NM 4651 is a novel monoclonal antibody developed by NovelMed Therapeutics. It functions as a complement activation modulator and is currently in preclinical development. The drug is available for licensing and is considered a new molecular entity. Preclinical trials have been conducted in the USA via parenteral administration.

Targets

Complement (Complement system)

Beyond the preview

Go deeper on NM 4651.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NM 4651.

Explore the full profile